Overview

Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This study was designed to test the addition of DMXAA (now known as ASA404) to carboplatin and paclitaxel in patients with NSCLC.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Antisoma Research
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Vadimezan